Symbiosis Pharmaceutical Services, a Scotland-based CMO, has launched a new bulk lyophilization service to support clients in the U.S., Europe and Asia with the manufacture of bulk intermediates and APIs.The company has expanded its sterile filling offering to be able to provide both aseptic and low bioburden clean room dispensing of bulk materials.
 
Colin MacKay, chief executive officer at Symbiosis Pharmaceutical Services, said, “This service launch has very much been driven by market demand from biotech and pharmaceutical companies requiring either a one-off batch or the ongoing bulk lyophilization of API or finished product.Our state-of-the-art facilities, licenses and technical capabilities enable us to offer such a service to the market in a reliable and responsive manner, helping meet clients’ product supply needs in a timely fashion.”
  
Symbiosis is able to lyophilze product in its GMP cleanroom suites in appropriate freeze drying trays, and, as part of the new service, will also support the development of an optimized cycle as well as analytical and microbial testing, labelling, controlled temperature storage and distribution.